Replies to post #213901 on Biotech Values

[Julius_Kelp]

"ADXS-NEO addendum: ADXS probably should have left the complex manufacturing of NEO to partner, AMGN, instead of trying to do it in-house."

Manufacturing for NEO is not being done in-house.

https://www.syntheticgenomics.com/synthetic-genomics-launches-cgmp-suite-for-pharmaceutical-quality-manufacturing-of-synthetic-dna-for-advaxis-clinical-trials/

[tx_farmer]

Isn"t that a 3 to 4 step process? ADXS shaved off weeks of a multiple month long process. Such idiots, right? or maybe they are increasing efficiency/profit potential!